Dr. Lynn Allison Baden, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1400 Centre St, #208, Newton, MA 02459 Phone: 617-558-0077 Fax: 617-558-1776 |
David A. Jones, M.D., PH.D. Dermatology Medicare: May Accept Medicare Assignments Practice Location: 2000 Washington St, Suite Blue-120, Newton, MA 02462 Phone: 617-969-0210 Fax: 617-527-6019 |
Valori D Treloar, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1172 Beacon St, Suite 402, Newton, MA 02461 Phone: 617-558-5580 Fax: 617-558-5581 |
News Archive
A UC Davis Health pediatric team presented a powerful case series of three teenagers who had unexplained breathing problems during the COVID-19 pandemic.
In this Forbes opinion piece, journalist Sarika Bansal examines five ways in which pharmaceutical companies can address neglected tropical diseases (NTDs), including creating cross-sectorial research partnerships for neglected diseases; joining patent pools for neglected diseases; donating drugs for neglected diseases; creating facilities dedicated to neglected disease research; and allowing scientists to work on neglected disease, both formally and informally.
The performance of commercially available serological tests in real patient samples and the correlates of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provided by IgG antibodies are still a matter of debate. A new bioRxiv preprint paper cross-examines the performance of several assays and proclaims the plaque reduction neutralization test (PRNT) as a method of choice.
Under heavy pressure from government regulators and insurance companies, more and more physicians across the country are learning to think like entrepreneurs. As recently as the late 1990s, there were only five or six joint M.D./M.B.A degree programs at the nation's universities, said Dr. Maria Y. Chandler, a pediatrician with an M.B.A. who is an associate clinical professor in the medical and business schools at the University of California, Irvine. "Now there are 65," she said.
Ludwig Cancer Research and the Cancer Research Institute have launched clinical trials evaluating an immunotherapy for the treatment of the brain cancer glioblastoma multiforme (GBM), and a combination of immunotherapies for a variety of solid tumors.
› Verified 6 days ago